Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer
- 117 Downloads
Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer. The exact role of the addition of chemotherapy is not established. We compared neoadjuvant therapy using chemoradiation (CRT) or hyperfractionated accelerated radiotherapy (HART).
Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge. A group of 50 patients was treated with a preoperative dose of 41.6 Gy of radiotherapy (RT) in two daily fractions of 1.6 Gy over 13 days immediately followed by surgery (HART). A second group of 96 patients received 45 Gy of conventionally fractionated RT in 25 daily fractions of 1.8 Gy combined with 5-fluorouracil–based chemotherapy followed by surgery within 4 to 6 weeks (CRT). Both groups were compared in terms of morbidity, pathological downstaging, local recurrence, and survival.
Both groups were comparable in terms of preoperative clinicopathological variables. The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT). Sphincter preservation was possible in 74% (HART) versus 83.5% (CRT) of patients (P = .013). The clinical anastomotic leak rate was 2% (HART) versus 2.2% (CRT). Pathological complete response was observed in 4% (HART) versus 18% (CRT) of the resected specimens (P = .002). A pelvic recurrence developed in 6% (HART) versus 4.4% (CRT) of patients (P = .98). Overall 5-year survival was 58% (HART) versus 66% (CRT) (P = .19); disease-free 5-year survival was 51% (HART) versus 62% (CRT) (P = .037).
Compared with preoperative HART followed by immediate surgery, preoperative CRT followed by a 6-week waiting period enhances pathological response and increases sphincter preservation rate. This could be explained by the addition of chemotherapy or the longer interval between neoadjuvant therapy and surgery. No statistically significant difference was observed in local control or overall survival.
KeywordsRectal cancer Neoadjuvant Total mesorectal excision Hyperfractionated accelerated therapy Chemoradiation
- 1.Glimelius B, Pahlman L. Preoperative or postoperative radiotherapy in rectal-carcinoma—a randomized multicenter trial. Lyon Chir 1991; 87:3–8Google Scholar
- 11.Hall EJ. Physical and biological basis of radiation therapy. In: Cox JD, Kian Ang K, eds. Radiation Oncology: Rationale, Technique, Results. St Louis: Mosby, 2003; 3–62Google Scholar
- 17.Sebag-Montefiore D, Brown G, Rutten H, et al. An international phase II study of capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. Eur J Cancer 2005; 3(Suppl):170Google Scholar
- 18.Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy—concept of additivity. Int J Radiat Oncol 1979; 5:85–91Google Scholar
- 25.Coucke PA, Sartorelli B, Cuttat JF, et al. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol 1995; 32:181–8Google Scholar
- 27.Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72:15–24PubMedCrossRefGoogle Scholar
- 28.Weinstein GD, Rich TA, Shumate CR, et al. Preoperative infusional chemoradiation and surgery with or without an electron-beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol 1995; 32:197–204Google Scholar
- 31.Bouliswassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery—trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984; 53:1811–8CrossRefGoogle Scholar
- 33.Conroy T, Bonnetain F, Chapet O, et al. Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: preliminary results of the FFCD 9203 randomized trial. J Clin Oncol 2004; 22:276sGoogle Scholar
- 34.Bosset JF, Calais G, Mineur L, et al. Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer? Report of the 22921 EORTC phase III trial. J Clin Oncol 2004; 22:246SGoogle Scholar